Skip to content

Clinical study of Wendan Decoction in improving erythrocyte immune function in patients with lung cancer complicated with hyperlipidemia

Clinical study of Wendan Decoction in improving erythrocyte immune function in patients with lung cancer complicated with hyperlipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2000003826
Enrollment
Unknown
Registered
2020-08-28
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Sponsors

Shanghai Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with non-small cell lung cancer were diagnosed by pathology or cytology; (2) Aged 18 to 80 years old (including 18 and 80 years old); (3) The expected survival time was more than 3 months; (4) Karnofsky score >=60; (5) No TCM decoction pieces or granules were used within 3 months before treatment; (6) Volunteer to participate in this study, can follow-up.

Exclusion criteria

Exclusion criteria: 1. Combined with other primary malignant tumors; 2. Patients with uncontrollable severe infection, hypertension, diabetes and liver and kidney dysfunction; 3. Pregnant and lactating women; 5. Patients or family members are not willing to sign the informed consent or do not agree with the author; 7. Any situations that researchers decide to exclude.

Design outcomes

Primary

MeasureTime frame
blood lipid;

Countries

China

Contacts

Public ContactGUO PENG

Shanghai Traditional Chinese Medicine Hospital

kwoppen@163.com+86 18116070357

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026